clinical trial · NCT05820672
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Ascendis Pharma Endocrinology Division A/S·—·recruiting·n = 900
Growth Hormone DeficiencyNo intervention
brief summary
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
started
Mar 20, 2023
primary completion
Mar 1, 2033
completion
Mar 1, 2033
last updated
Apr 21, 2026
detailed description
Patients will be treated according to routine clinical practice, and no additional visits, examinations or tests will be required beyond those performed as part of routine clinical practice except for COAs.
official title
A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol